High clinical and morphologic response using 90Y-DOTA-octreotate sequenced with 177Lu-DOTA-octreotate induction peptide receptor chemoradionuclide therapy (PRCRT) for bulky neuroendocrine tumours
Crossref DOI link: https://doi.org/10.1007/s00259-016-3527-x
Published Online: 2016-09-27
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kong, Grace http://orcid.org/0000-0002-0834-6888
Callahan, Jason
Hofman, Michael S.
Pattison, David A.
Akhurst, Tim
Michael, Michael
Eu, Peter
Hicks, Rodney J.
License valid from 2016-09-27